In this issue of THE JOURNAL, Black and colleagues1 report
the results of an aborted clinical trial. In the Controlled Onset Verapamil
Investigation of Cardiovascular End Points (CONVINCE) study, a large randomized
double-blind equivalence trial with many strengths, the investigators compared
a controlled-onset extended-release formulation of the calcium channel blocker
verapamil with standard therapies (atenolol or hydrochlorothiazide) for hypertension.
Randomization was stratified on type of standard care—diuretics or β-blockers—with
the result that there were, in effect, 2 parallel trials within CONVINCE,
verapamil vs each of the other 2. When the rates of withdrawal from treatment
were noted to be higher than expected, the sample size was increased from
15 000 to 16 600 with a new target of 2246 primary events, which
included first myocardial infarction, stroke, or cardiovascular disease–related
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 47
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.